LEADER 03512nam  22005891  450 
001 9910789125703321
005 20230725054656.0
010   $a1-908986-59-X
035   $a(CKB)3710000000083545
035   $a(EBL)3410357
035   $a(SSID)ssj0001084412
035   $a(PQKBManifestationID)11975809
035   $a(PQKBTitleCode)TC0001084412
035   $a(PQKBWorkID)11022450
035   $a(PQKB)11643876
035   $a(MiAaPQ)EBC3410357
035   $a(Au-PeEL)EBL3410357
035   $a(CaPaEBR)ebr10827988
035   $a(CaONFJC)MIL577719
035   $a(OCoLC)923424667
035   $a(EXLCZ)993710000000083545
100   $a20090819d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEvidence-based management of lipid disorders /$fMaud N. Vissers, John J.P. Kastelein, Erik S. Stroes, [editors]
210  1$aHarley :$cTFM,$d2010.
215   $a1 online resource (322 p.)
300   $aDescription based upon print version of record.
311   $a1-903378-71-0 
320   $aIncludes bibliographical references and index.
327   $a""COVER FRONT""; ""Contents""; ""Foreword""; ""Contributors""; ""Acknowledgements""; ""Using evidence-based medicine""; ""Chapter 1 How much evidence is enough?""; ""Chapter 2 A brief review of lipoprotein metabolism""; ""Chapter 3 Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases""; ""Chapter 4 Are LDL cholesterol-lowering functional food ingredients successful in the long term?""; ""Chapter 5 Evidence-based treatment of primary hypo- and hypercholesterolemic disorders""; ""Chapter 6 Does raising HDL protect against atherosclerosis?""
327   $a""Chapter 7 How do we diagnose hypertriglyceridemia in clinical practice and what are the consequences for treatment?""""Chapter 8 The optimal treatment of patients with familial combined hyperlipidemia""; ""Chapter 9 How to manage lipid and lipoprotein disorders in children""; ""Chapter 10 Contribution of the atherogenic dyslipidemic phenotype to the increased cardiovascular disease risk of the metabolic syndrome and diabetes mellitus""; ""Chapter 11 What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels?""
327   $a""Chapter 12 The link between chronic inflammatory diseases and cardiovascular risk""""Chapter 13 What is the evidence for a physiological and pathogenic role of lipoprotein (a)?""; ""Chapter 14 Sitosterolemia;  xenophobia for the body""; ""Chapter 15 How can we deal with inborn errors in cholesterol and bile acid biosynthesis?""; ""Chapter 16 Differential diagnosis of patients with xanthomas and xanthelasmata""; ""Chapter 17 When should we fear statin interactions?""; ""Chapter 18 What are the considerations in patients who are statin a???intoleranta????""; ""Index""; ""COVER BACK""
606   $aLipids$xMetabolism$xDisorders$xTreatment
606   $aEvidence-based medicine
615  0$aLipids$xMetabolism$xDisorders$xTreatment.
615  0$aEvidence-based medicine.
676   $a616.399706
700   $aVissers$b Maud N$01551283
701   $aVissers$b Maud N$01551283
701   $aKastelein$b John J. P$01551284
701   $aStroes$b Erik S$01551285
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910789125703321
996   $aEvidence-based management of lipid disorders$93810701
997   $aUNINA